Advertisement
Screener

NANOVIRICIDES, INC. (NNVC) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

NANOVIRICIDES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

NANOVIRICIDES, INC. (NNVC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2015-12-31, per its 10-Q filed 2016-02-09.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2016-02-09

  • NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2015-09-30 was 0.00%.
  • NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2014-12-31 was 0.00%.
  • NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2014-03-31 was 0.00%.
  • NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2013-09-30 was 0.00%.
  • NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 0.00%.
  • NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2014 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 1 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2015-12-310.00%
10-Q · filed 2016-02-09
2015-09-300.00%
10-Q · filed 2015-11-09
2015-06-300.00%
10-K · filed 2015-09-14
2015-03-310.00%
10-Q · filed 2015-05-15
2014-12-310.00%
10-Q · filed 2015-02-25
2014-08-150.00%
10-Q/A · filed 2015-02-23
2014-06-300.00%
10-K · filed 2015-09-14
2014-03-310.00%
10-Q · filed 2014-05-15
2014-01-310.00%
10-K · filed 2014-09-30
2013-09-300.00%
10-K · filed 2014-09-30
0.00%
10-Q · filed 2014-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30